藥物adagrasib有效抑制攜帶KRASG12C突變的癌癥類型在治療胃腸道癌癥患者中展現(xiàn)出臨床活性

發(fā)布時(shí)間：

2022-02-15

來源：

專業(yè)提供(ATCC,DSMZ,RCB,JCRB細(xì)胞庫(kù)源細(xì)胞、動(dòng)物實(shí)驗(yàn)、CRO服務(wù)、SCI潤(rùn)色)

作者：

【如需咨詢購(gòu)買細(xì)胞或技術(shù)服務(wù),請(qǐng)點(diǎn)擊24小時(shí)客服咨詢或留言哦】

閱讀數(shù)：

胃腸道癌癥是一些最常被診斷出的人類癌癥，這類癌癥往往與患者不良的生存結(jié)局有關(guān)，而藥物adagrasib能特異性地靶向作用KRASG12C基因突變，該基因突變?cè)谖改c道癌癥中非常常見，其能抑制機(jī)體胃腸道的功能

　　胃腸道癌癥是一些最常被診斷出的人類癌癥，這類癌癥往往與患者不良的生存結(jié)局有關(guān)，而藥物adagrasib能特異性地靶向作用KRASG12C基因突變，該基因突變?cè)谖改c道癌癥中非常常見，其能抑制機(jī)體胃腸道的功能。（推薦閱讀：MKN74人胃癌細(xì)胞、FU97人胃癌細(xì)胞、SNU-16人胃癌細(xì)胞、NS-3人胃癌細(xì)胞、GTL16人胃癌細(xì)胞）
　　研究者Tanios Bekaii-Saab博士表示，我們對(duì)藥物adagrasib進(jìn)行了一系列研究，結(jié)果發(fā)現(xiàn)，其在治療攜帶KRAS G12C突變的胃腸道癌癥患者中具有非常良好的臨床活性，包括胰腺癌、膽道癌和其它上消化道癌癥等，近日，Tanios Bekaii-Saab博士在召開的美國(guó)臨床腫瘤學(xué)會(huì)泌尿生殖系統(tǒng)癌癥研討會(huì)上介紹了作為KRYSTAL-1臨床試驗(yàn)（NCT03785249）的一部分的研究結(jié)果。

　　研究者Bekaii-Saab表示，攜帶KRAS基因突變的癌癥患者的預(yù)后往往較差，而科學(xué)家們也在一直研究嘗試靶向作用KRAS G12C，但均以失敗而告終；KRAS G12C在這組癌癥中所有的KRAS突變中占比不到5%的比例。相關(guān)研究數(shù)據(jù)最近在研討會(huì)上公布，研究者發(fā)現(xiàn)，藥物adagrasib不僅能有效抑制攜帶KRASG12C突變的癌癥類型，還在治療胃腸道癌癥患者中展現(xiàn)出了一定的臨床活性。（推薦閱讀：WiDr人大腸癌細(xì)胞、C26小鼠結(jié)腸癌、H508人結(jié)腸癌細(xì)胞）
　　在2期隊(duì)列研究中所有接受這種新型療法的胃腸道癌癥患者的疾病都得到了控制，近一半的患者表現(xiàn)出了明顯且持久的腫瘤萎縮效應(yīng)和證據(jù)。研究者表示，在治療一組結(jié)果表現(xiàn)較差的疾病上，這些研究結(jié)果或許令人印象非常深刻，而研究人員對(duì)這些研究發(fā)現(xiàn)感到非常驚喜，因?yàn)樗麄冎笆褂玫牧硪活愊嗨扑幬锏慕?jīng)驗(yàn)在這一特殊的患者群體中所得到的結(jié)果往往令人失望。
　　目前研究人員正在對(duì)adagrasib藥物進(jìn)行研究，如果這些較好的治療效果的趨勢(shì)繼續(xù)下去的話，這種藥物最終或有望作為一種新型療法來幫助治療胰腺癌、膽道癌以及其它胃腸道癌癥等。（推薦閱讀：KP-1N人胰腺癌細(xì)胞、HS766T、COLO-587、MPANC-96人胰腺癌細(xì)胞、胰腺癌原位模型）
　　原始出處：
　　Researchers identify promising drug to treat gastrointestinal cancers
　　by Joe Dangor, Mayo Clinic
　　Gastrointestinal cancers are some of the most commonly diagnosed cancers, and they continue to be associated with poor survival outcomes. The drug adagrasib specifically targets the KRASG12C gene mutation that is common in gastrointestinal cancers and inhibits gastrointestinal function.
　　Tanios Bekaii-Saab, M.D., an investigator from Mayo Clinic Cancer Center, has conducted research on adagrasib that has demonstrated promising clinical activity in patients with gastrointestinal cancers that harbor KRAS G12C mutations, including pancreatic cancer, biliary tract cancer and other upper gastrointestinal cancers. Dr. Bekaii-Saab recently presented the results of this research as part of the KRYSTAL-1 clinical trial (NCT03785249) at the American Society of Clinic Oncology's Genitourinary Cancers Symposium.
　　"The prognosis for patients whose cancer harbors a KRAS gene mutation is particularly poor, and researchers' attempts to target KRAS G12C, which represents less than 5% of all KRAS mutations in this group of cancers, have failed until only recently," says Dr. Bekaii-Saab.
　　"Our data recently presented at ASCO GI (the symposium) showed that adagrasib not only inhibits cancers with a KRASG12C mutation effectively, but also showed promising clinical activity in patients with gastrointestinal cancers."
　　Dr. Bekaii-Saab says the gastrointestinal cancers for all patients treated in this phase 2 cohort were controlled, with close to half showing evidence of significant and durable tumor shrinkage.
　　"These results were very impressive in treating a group of diseases that tend to have a particularly poor outcome," says Dr. Bekaii-Saab. "We were pleasantly surprised by these findings, given that our previous experience with another similar agent was disappointing in this particular group of patients."
　　He says research with adagrasib is ongoing. If these trends continue, the drug may eventually prove to be a new option for patients with pancreatic, biliary tract and other gastrointestinal cancers.......